400,790 Shares in Core Laboratories Inc. $CLB Acquired by Hotchkis & Wiley Capital Management LLC

Key Points

• Hotchkis & Wiley Capital Management LLC acquired 400,790 shares of Core Laboratories Inc., representing about 0.85% of the company, valued at approximately $6 million.
• Core Laboratories recently announced a quarterly dividend of $0.01 per share, reflecting an annual yield of 0.4% with a payout ratio of 6.45%.
• Analysts have given Core Laboratories a consensus rating of "Hold" with a target price of $12.50, following various upgrades and downgrades from research firms.

Hotchkis & Wiley Capital Management LLC bought a new position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 400,790 shares of the oil and gas company's stock, valued at approximately $6,008,000. Hotchkis & Wiley Capital Management LLC owned approximately 0.85% of Core Laboratories as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Ridgewood Investments LLC grew its position in Core Laboratories by 2.7% in the first quarter. Ridgewood Investments LLC now owns 33,486 shares of the oil and gas company's stock valued at $502,000 after acquiring an additional 874 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Core Laboratories by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,723 shares of the oil and gas company's stock valued at $463,000 after acquiring an additional 960 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Core Laboratories by 5.0% during the 1st quarter. Mackenzie Financial Corp now owns 24,556 shares of the oil and gas company's stock valued at $368,000 after buying an additional 1,170 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Core Laboratories by 92.5% during the 1st quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock valued at $43,000 after buying an additional 1,387 shares during the last quarter. Finally, Captrust Financial Advisors boosted its stake in shares of Core Laboratories by 3.2% during the 4th quarter. Captrust Financial Advisors now owns 55,527 shares of the oil and gas company's stock valued at $961,000 after buying an additional 1,728 shares during the last quarter. Institutional investors and hedge funds own 97.81% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on CLB. Zacks Research upgraded Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Citigroup reduced their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Stifel Nicolaus dropped their target price on Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a research report on Wednesday, July 16th. Finally, Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $12.50.

Core Laboratories Price Performance

Shares of CLB opened at $11.0970 on Tuesday. The stock's fifty day moving average is $11.55 and its 200-day moving average is $12.69. The firm has a market capitalization of $520.34 million, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 3.37 and a beta of 1.41. Core Laboratories Inc. has a one year low of $9.72 and a one year high of $21.83. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.70 and a current ratio of 2.27.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.01. The firm had revenue of $130.16 million for the quarter, compared to analyst estimates of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.Core Laboratories's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. Equities analysts anticipate that Core Laboratories Inc. will post 0.96 EPS for the current year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Monday, August 4th. Core Laboratories's payout ratio is presently 6.45%.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories Inc. (NYSE:CLB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.